Imfinzi is first immunotherapy to show both significant survival benefitand improved, durable responses in extensive-stage small cell lung cancer
9 Sept 2019 08:38 BST Imfinzi is first immunotherapy to show both significant survival benefitand improved, durable responses in extensive-stage small cell lung cancer In the Phase III CASPIAN trial Imfinzi at a fixed, convenient dose improvedsurvival with either a cisplatin or carboplatin chemotherapy backbone AstraZeneca today presented detailed results from the Phase III CASPIAN trial, showing Imfinzi (durvalumab) significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC). Imfinzi in combination with